AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 66(4), 2002, pp. 348-358
Copyright © 2002 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Todd, C.
Right arrow Articles by Colley, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Todd, C.
Right arrow Articles by Colley, D.
Related Collections
Right arrow Schistosomiasis
American Journal of Tropical Medicine and Hygiene, Vol 66, Issue 4, 348-358
Copyright © 2002 by American Society of Tropical Medicine and Hygiene

Research Articles


Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni

CW Todd and DG Colley

Clinical trials to evaluate schistosomal vaccines are in progress. We discuss the desired characteristics of such a vaccine, propose a product profile, and consider the clinical and pre-clinical studies needed for its licensure, within practical and ethical constraints. We believe that licensure of a schistosomal vaccine will be greatly facilitated by resolution of the following issues: identification of the human immunoprotective antigens and mechanisms; induction of the appropriate responses by adjuvanted vaccines; understanding the effect of immunization on immunopathology; development of an improved serologic assay to determine worm burden; generation of approximately $500 million to fund the project; and development of a physical infrastructure with trained professionals in disease-endemic countries to perform Phase III clinical trials. We also believe that development of a schistosomal vaccine, while a long range goal, is possible and desirable, and we have indicated some of the practical steps that will be required to achieve this laudable accomplishment.


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
D. P. McManus and A. Loukas
Current Status of Vaccines for Schistosomiasis
Clin. Microbiol. Rev., January 1, 2008; 21(1): 225 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. M. Ganley-Leal, P. N. Mwinzi, C. B. Cetre-Sossah, J. Andove, A. W. Hightower, D. M. S. Karanja, D. G. Colley, and W. E. Secor
Correlation between Eosinophils and Protection against Reinfection with Schistosoma mansoni and the Effect of Human Immunodeficiency Virus Type 1 Coinfection in Humans
Infect. Immun., April 1, 2006; 74(4): 2169 - 2176.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. M. Cook, C. Carvalho-Queiroz, G. Wilding, and P. T. LoVerde
Nucleic Acid Vaccination with Schistosoma mansoni Antioxidant Enzyme Cytosolic Superoxide Dismutase and the Structural Protein Filamin Confers Protection against the Adult Worm Stage
Infect. Immun., October 1, 2004; 72(10): 6112 - 6124.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
C. Carvalho-Queiroz, R. Cook, C. C. Wang, R. Correa-Oliveira, N. A. Bailey, N. K. Egilmez, E. Mathiowitz, and P. T. LoVerde
Cross-Reactivity of Schistosoma mansoni Cytosolic Superoxide Dismutase, a Protective Vaccine Candidate, with Host Superoxide Dismutase and Identification of Parasite-Specific B Epitopes
Infect. Immun., May 1, 2004; 72(5): 2635 - 2647.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. M. Mentink-Kane, A. W. Cheever, R. W. Thompson, D. M. Hari, N. B. Kabatereine, B. J. Vennervald, J. H. Ouma, J. K. Mwatha, F. M. Jones, D. D. Donaldson, et al.
IL-13 receptor {alpha} 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis
PNAS, January 13, 2004; 101(2): 586 - 590.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society of Tropical Medicine and Hygiene.